ABSTRACT

Management of advanced intrahepatic cholangiocarcinoma (iCCA) is challenging and overall survival is poor. Progress in the development of new therapeutic options for metastatic cholangiocarcinoma (CCA) has been slow; hence, to date, there are no approved second-line agents in this setting. Although the development of immune checkpoint inhibitors has significantly improved overall survival in a variety of malignancies, there has not been a clinically important impact in CCA. This report presents a 66-year-old patient with chemotherapy-refractory iCCA who experienced a prolonged response to immunotherapy. Tumor genome profiling revealed a high tumor mutation burden of 17 mutations per megabase in the absence of microsatellite instability. He was started on immunotherapy with nivolumab and has experienced an ongoing response for 16 months without clinical symptoms and only minimal radiologic disease.

Intrahepatic cholangiocarcinoma (iCCA) remains recalcitrant to treatment, with a median survival of only 26 to 30 months in localized and resectable disease.1,2 In the more common locally advanced/metastatic setting, outcomes are even more dire. A median overall survival of 11.7 months was reported with combination gemcitabine + cisplatin in the first-line setting.3 Despite this high mortality and reports of increasing incidence of iCCA,4 little progress has been made in the development of new therapeutic options. Indeed, there are no agents (single-therapy or combination) approved in the second line for advanced/metastatic iCCA, and in this era of precision medicine and immune therapy, there are no biologic agents used outside clinical trials. Preliminary results of the KEYNOTE-028 study (ClinicalTrials.gov Identifier: NCT02054806) showed no radiographic complete response among 24 patients with PD-L1–positive (>1% expression threshold) advanced biliary tree cancer treated with pembrolizumab. The overall response rate was 17%, and 5 patients remained on treatment for 40+ to 42+ weeks at the time of the report.5

This report presents a patient with chemotherapy-refractory recurrent metastatic iCCA who has experienced a durable response to third-line anti–PD-1 immune checkpoint inhibitor (ICI) therapy for >12 months. Targeted genetic sequencing before treatment revealed an unusually high tumor mutational burden (TMB), and we posit that this is the reason for the prolonged response.

Case Report

A 66-year-old white man with a history of type 2 diabetes mellitus presented to the emergency room after a near-syncopal event. He was noted to be jaundiced, and an ultrasound scan of the liver revealed a 2.4 × 2.0-cm hypoechoic mass in the central right hepatic lobe. This was confirmed by subsequent imaging with CT and MRI. No lymph node involvement or evidence of lesions suspicious for metastasis was evident within the abdomen or thorax. Cytology through fine-needle aspiration of the mass via an endoscopic ultrasound procedure...
The patient underwent exploratory laparotomy, and right hepatectomy, cholecystectomy, extrahepatic bile duct resection, and Roux-en-Y hepaticojejunostomy were performed in June 2015. Within the right hepatectomy specimen, there was a 3.3-cm poorly differentiated CCA with involvement of the vascular (hepatic vein) margin. The mass was staged as poorly differentiated pT2N0 CCA (stage II) after R1 resection; CA 19-9 level was not elevated (<37 U/mL). The patient received adjuvant chemoradiation with capecitabine and 50.4 Gy of radiation in 28 fractions.

Three months after chemoradiation, CT revealed indeterminate subcentimeter pulmonary nodules. Repeat scan 3 months later showed a 2.2-cm left hepatic lobe mass. No pulmonary involvement was seen. Biopsy results of the lesion in the left hepatic lobe were consistent with metastatic CCA. At that point, the patient received 8 cycles of chemotherapy with gemcitabine + cisplatin. At the end of systemic therapy in July 2016, imaging revealed a partial response in the left hepatic lobe mass, which now measured 1.6 cm, with no other lesions. A PET/CT scan obtained in August 2016 to assess residual tumor activity and rule out more widespread disease before planned local therapy for the liver disease confirmed the liver mass (2.3 cm; standardized uptake value [SUV], 14.7) and also showed a 1.6-cm hypermetabolic umbilical nodule (SUV, 11.4) and a 1.3-cm perirectal nodule (SUV, 11.7). The patient was started on systemic therapy with second-line therapy with combination 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) and received palliative stereotactic body radiation therapy to the liver and painful umbilical nodules. Upon further disease progression, he was referred to our phase I clinic.

At his first visit to our clinic, he reported that FOLFOX had recently been stopped in December 2016 after 6 cycles due to clinical (worsening abdominal pain and ascites) and radiologic progression. He reported mild abdominal pain and fatigue, but his ECOG performance status was 1, with minimal adverse effects from the previous chemotherapy. The right hepatectomy tumor specimen was sent for panel-based tumor genomic profiling on the FoundationOne platform (Foundation Medicine),6 which revealed a KRAS (exon 4) A146T mutation and BRCA2 R3052Q mutation (Table 1). Results of PD-L1 staining were negative. Importantly, the testing also found a TMB of 17 mutations/Mb in the absence of microsatellite instability (MSI). On the basis of high TMB, the patient was started on anti–PD-1 antibody therapy (nivolumab) in March 2017. Interval imaging 2 months after initiation of therapy showed a stable 1.5-cm left hepatic lobe nodule, a partial response in the perirectal lesion, and a complete response in previously described inguinal canal nodules. To date, the patient has had minimal residual disease since scans obtained 7 months into treatment (Figure 1). His clinical symptoms (abdominal pain and ascites) have completely resolved, and he has continued to receive nivolumab with minimal adverse events except for grade 1 fatigue.

**Discussion**

ICIs (immunotherapy) have transformed the management of a variety of advanced and metastatic solid tumors, particularly melanoma and non–small cell lung cancer (NSCLC). In addition to improving progression-free and overall survival, immune therapy has the potential to produce very prolonged responses and possibly even cures in patients with previously incurable cancer.7 However, the therapeutic benefit of immunotherapy has been inconsistent across the panoply of tumors for which it is used. A number of patients with melanoma or NSCLC have disappointing responses to immunotherapy. There is therefore an ongoing search for biomarkers that predict response to therapy.

PD-L1 expression is the most widely studied biomarker of response to immune therapy and is the most commonly used metric. Higher expression of PD-L1 is associated with improved benefit from immune therapy in a number of cancer types.8 However, the limitations of PD-L1 expression as a predictor of response to immune

<table>
<thead>
<tr>
<th>Key Molecular Alterations</th>
<th>Variants of Unknown Significance</th>
<th>PD-L1 Immunohistochemical Analysis (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>KRAS A146T</td>
<td>ROS1 K2099N</td>
<td>Tumor score, 0</td>
</tr>
<tr>
<td>BRCA2 R3052Q</td>
<td>AXL Q361P</td>
<td>Tumor-infiltrating immunocytes, 0</td>
</tr>
<tr>
<td>KDM6A R971fs*8</td>
<td>FGF23 P153A</td>
<td></td>
</tr>
<tr>
<td>SPTA1 R250H</td>
<td>CHEK2 A215T</td>
<td></td>
</tr>
<tr>
<td>TMB17 mutations/megabase</td>
<td>TSC2 R901C</td>
<td></td>
</tr>
</tbody>
</table>

*Curated list of alterations potentially targetable with FDA-approved drugs from the appendix of variants of unknown significance provided within the FoundationOne tumor genomic profile result.
therapy have been documented, especially given that responses are also seen in “PD-L1-negative tumors” across tumor types.

Mismatch repair (MMR) deficiency (often defined by MSI) is caused by loss or methylation-based suppression of the genes that encode MMR proteins (MLH1, MSH2, MSH6, PMS2, and EpCAM). MMR deficiency is another established predictive marker for response to immune therapy. In a pivotal phase II study (ClinicalTrials.gov identifier: NCT01876511), treatment with pembrolizumab was associated with a response rate of 53% in MMR-deficient tumors (colorectal and noncolorectal cancers) compared with 0% for MMR-proficient tumors. MMR deficiency leads to a significant increase in mutation frequency and consequently a higher neoantigen burden of the tumor. This increase in neoantigen quantity and diversity is thought to stimulate an improved immune response to the tumor. In the absence of MMR deficiency, an increase in TMB also seems to be an independent and bona fide predictive biomarker of response to ICI therapy. For example, in melanoma, Snyder et al showed that presence of >100 non-synonymous mutations per exome was associated with an improved response rate and survival in response to anti–CTLA-4 antibody therapy. Similar findings have been described with anti–PD-1 therapy in NSCLC. For melanoma and lung cancer, TMB may be driven by UV light exposure and chemically driven mechanisms rather than by MMR loss.

Biliary tree cancers are generally characterized by a low TMB, with median TMB of 2.9 to 5.7 mutations/Mb reported. The iCCA in our patient had a TMB of 17 mutations/Mb, which is impressive, given that Salem et al reported a high TMB (threshold of 15 mutations/Mb) in only 2.9% of patients with biliary tract cancer. The high TMB was the motivation for recommending anti–PD-1 therapy to our patient.

Use of TMB as a marker for response to ICI therapy is still evolving. A major challenge is defining a cutoff for low versus high TMB. Although a level of >20 mutations/Mb is reported in the literature for defining a high TMB, the threshold adopted in clinical practice is usually lower. In a recent examination of the efficacy of combination ipilimumab + nivolumab in NSCLC, a clinically relevant, less restrictive TMB threshold of 10 mutations/Mb was used. It is also not clear whether this should be a
dichotomous rather than a continuous classification, and some investigators have defined an intermediate TMB.13 Furthermore, a case could be made for individualizing TMB classification based on tumor histology, because a TMB of 10, which may be considered low in NSCLC, may have a different connotation in pancreatic ductal adenocarcinoma and biliary tree cancer or in other malignancies with generally low tumor mutations. Answering these questions will become important as TMB becomes more widely validated as a prognostic biomarker for immunotherapy.

Interestingly, although next-generation sequencing showed that the CCA was microsatellite stable (MSS), paired tumor and normal tissue immunohistochemistry (IHC) showed loss of MLH1/PMS2 expression in the tumor. Subsequent PCR-based MSI analysis using the Promega kit did not show alterations in any microsatellite locus, consistent with MSS. This was in agreement with next-generation sequencing results. The discordance rate between IHC and PCR for detecting MSI is <5%, and the performance (and interpretation) of IHC is more prone to errors than PCR-based testing.20,21 Importantly, although testing for MSI and MMR proteins is standardized and validated in colorectal and endometrial cancer, this is not the case in other Lynch syndrome–associated malignancies. For example, a review of 834 cases of ovarian cancer reported a concordance rate of only 68% between IHC- and PCR-based testing.22 This suggests that data for colorectal cancer cannot be extrapolated to other malignancies. In our patient, the agreement between PCR and next-generation sequencing increased our confidence that he had MSS disease, although it can be argued that MLH1/PMS2 loss by IHC is sufficient to identify MMR deficiency. Nevertheless, we did not perform any tests to directly assess MLH1 promoter hypermethylation. Investigators have reported MLH1 promoter hypermethylation in approximately 20% of MSS colorectal cancer cases, although in this series, it did not translate to loss of MLH1 expression.23 Furthermore, in a cohort of patients with ovarian cancer, approximately 10% (3 of 28 samples) of MSS (PCR-based assay) samples had MLH1 promoter hypermethylation.24 We therefore concede that high TMB may be related to MMR deficiency secondary to MLH1 alteration. Indeed, in the absence of a high tumor mutational burden, MLH1 loss would be a valid indication for the use of ICI therapy in our patient.

Another interesting hypothesis regarding our patient is whether genomic instability caused by the BRCA mutation (independent of a high TMB) may have contributed to prolonged survival and the durable response to immunotherapy. BRCA mutations are rare in CCA,25,26 and the BRCA2 R3052Q mutation detected in our patient was considered a variant of unknown significance. The role of BRCA mutations specifically and homologous recombination deficiency (HRD; marker of genomic instability) in determining response to immunotherapy has not been clearly defined. A few reports link HRD to a high TMB,27,28 but data are still early. Because HRD has been explored as a biomarker for the use of PARP inhibitors and may become important for immunotherapy, it is important to develop an assay that would be applicable across malignancies. The HRD assay that is currently available was developed for breast and ovarian cancers.

Conclusions

This report presents a patient with chemotherapy-resistant iCCA and a high TMB who experienced prolonged disease control with immunotherapy. This impressive response highlights the usefulness of tumor genome profile testing as a tool for guiding therapy. These findings also strengthen the case for exploring high TMB as a tumor agnostic biomarker of response to immune therapy. We highlight a potential challenge with the current approach to detecting MSI and the need to validate this approach in other Lynch syndrome–associated malignancies.


